Advertisement
Letter to the Editor| Volume 68, ISSUE 4, P847-849, April 2018

Download started.

Ok

HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient

  • Jie Wang
    Affiliations
    State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
    Search for articles by this author
  • Qiuju Sheng
    Affiliations
    Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China
    Search for articles by this author
  • Yang Ding
    Affiliations
    Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China
    Search for articles by this author
  • Ran Chen
    Affiliations
    State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
    Search for articles by this author
  • Xiaofeng Sun
    Affiliations
    State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
    Search for articles by this author
  • Xiangmei Chen
    Affiliations
    State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
    Search for articles by this author
  • Xiaoguang Dou
    Correspondence
    Corresponding authors. Addresses: State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China. Tel.: +86 10 82805136; fax: +86 10 82805136 (F. Lu), or Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China (X. Dou).
    Affiliations
    Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China
    Search for articles by this author
  • Fengmin Lu
    Correspondence
    Corresponding authors. Addresses: State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China. Tel.: +86 10 82805136; fax: +86 10 82805136 (F. Lu), or Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, China (X. Dou).
    Affiliations
    State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China
    Search for articles by this author
Published:November 04, 2017DOI:https://doi.org/10.1016/j.jhep.2017.10.030
      With great interest, we read the manuscript “Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients” by Wang et al. published in Journal of Hepatology.
      • Wang J.
      • Yu Y.
      • Li G.
      • Shen C.
      • Meng Z.
      • Zheng J.
      • et al.
      Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
      The authors revealed that serum hepatitis B virus (HBV) RNA levels reflected intrahepatic transcriptional activity of covalently closed circular DNA (cccDNA) and were associated with liver histopathology in patients receiving entecavir (ETV) therapy. Moreover, quasispecies analysis found that serum HBV RNA resembled intrahepatic viral RNA but not cccDNA, implying that the nascent variants of HBV RNA detected in liver biopsy samples were not present in cccDNA under nucleos(t)ide analogues (NAs) treatment. In addition, the authors proposed that the viral forms in the reservoir of HBV RNA virion-like particles might be composed of viral transcriptional products from static (persistent present) active cccDNA and newly produced viral progeny from de novo infections. Since serum HBV DNA was undetectable in these ETV-treated patients, we postulated that the presence of HBV RNA virion-like particles might contribute to the de novo infections. Based on the fact that the cells transfected with pregenomic RNA (pgRNA) of a DNA virus can produce complete infectious viruses,
      • Huang M.J.
      • Summers J.
      Infection initiated by the RNA pregenome of a DNA virus.
      the infection potential of HBV RNA virion-like particles containing HBV pgRNA has been previously proposed.
      • Jansen L.
      • Kootstra N.A.
      • van Dort K.A.
      • Takkenberg R.B.
      • Reesink H.W.
      • Zaaijer H.L.
      Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues.
      • Wang J.
      • Shen T.
      • Huang X.
      • Kumar G.R.
      • Chen X.
      • Zeng Z.
      • et al.
      Serum hepatitis B virus is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.

      Linked Article

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      Author names in bold designate shared co-first authorship

        • Wang J.
        • Yu Y.
        • Li G.
        • Shen C.
        • Meng Z.
        • Zheng J.
        • et al.
        Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.
        J Hepatol. 2018; 68: 16-24
        • Huang M.J.
        • Summers J.
        Infection initiated by the RNA pregenome of a DNA virus.
        J Virol. 1991; 65: 5425-5439
        • Jansen L.
        • Kootstra N.A.
        • van Dort K.A.
        • Takkenberg R.B.
        • Reesink H.W.
        • Zaaijer H.L.
        Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues.
        J Infect Dis. 2016; 213: 224-232
        • Wang J.
        • Shen T.
        • Huang X.
        • Kumar G.R.
        • Chen X.
        • Zeng Z.
        • et al.
        Serum hepatitis B virus is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.
        J Hepatol. 2016; 65: 700-710
        • Lam A.M.
        • Ren S.
        • Espiritu C.
        • Kelly M.
        • Lau V.
        • Zheng L.
        • et al.
        Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants.
        Antimicrob Agents Chemother. 2017; 61: e00680
        • Pan C.Q.
        • Duan Z.
        • Dai E.
        • Zhang S.
        • Han G.
        • Wang Y.
        • et al.
        Tenofovir to prevent hepatitis B transmission in mothers with high viral load.
        N Engl J Med. 2016; 374: 2324-2334
        • Zhang H.
        • Pan C.Q.
        • Pan Q.
        • Tian R.
        • Yan M.
        • Liu X.
        Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice.
        Hepatology. 2014; 60: 468-476
        • European Association for the Study of the Liver
        EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection.
        J Hepatol. 2017; 67: 370-398
        • Sarin S.K.
        • Kumar M.
        • Lau G.K.
        • Abbas Z.
        • Chan H.L.
        • Chen C.J.
        • et al.
        Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
        Hepatol Int. 2016; 10: 1-98
        • Ding Y.
        • Sheng Q.
        • Ma L.
        • Dou X.
        Chronic HBV infection among pregnant women and their infants in Shenyang, China.
        Virol J. 2013; 10: 17